PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Labcorp, CCORN Ink Partnership to Address Precision Oncology Disparities
The Community Clinical Oncology Research Network will leverage Labcorp's comprehensive genomic profiling test to build out a registry of diverse patient data.Â
FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC
Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.
Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
Inspirata, Flagship Bio Enter Digital Pathology Pact
The deal provides clinicians with digital access to Flagship Bio's TissueInsight via Inspirata's Dynamyx digital pathology product.